IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

Founded in 2016, we are a biotechnology company focused on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. We have one Core Product, CM310, an antagonist antibody against interleukin-4 receptor α-subunit (IL-4Rα ), intended to treat various allergic diseases, such as moderate-tosevere atopic dermatitis (AD), moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), and potentially chronic obstructive pulmonary disease (COPD). We have been able to continuously discover and develop new drug candidates in these therapeutic areas and in addition to our Core Product, our pipeline includes eight drug candidates at various stages of development, of which five are clinical-stage drug candidates that each are among the first three domestically-developed for its target or in its class to have obtained IND approval in China and/or the U.S., and three are in investigational new drug (IND)-enabling stage. All of our drug candidates are currently in the development stage, and we may not be able to ultimately develop and market our drug candidates, including CM310, successfully. Our proprietary product pipeline reflects our market insight and employs the most recent scientific findings. Driven by economic growth and the healthcare system reform, medical expenditures have been rising significantly in the first two decades of the new millennium. China is undergoing an epidemiological transition from the prevalence of infectious diseases to that of cancer and other chronic diseases, as a result of rapid urbanization, life style shifts, and environmental changes. These fundamental and ongoing trends present new challenges for public health, and have revealed emerging underserved disease areas that impose a significant social burden to be addressed. Based on a solid foundation in biomedical research, we have built in-house drug discovery and development technologies that are complemented by our collaboration with other pharmaceutical and biotechnology companies. These comprise an innovative antibody discovery platform and a proprietary novel T cell engager1 (nTCE) bispecific antibody platform. To support our research and discovery, we have established a fully-integrated platform encompassing all of the key functions in the biologic drug development. These include target validation, lead generation and optimization, preclinical evaluation, process development, translational research, clinical development and manufacture. This integrated platform has enabled us to rapidly and cost-effectively identify, build, expand and advance our diversified pipeline of innovative and differentiated antibody-based therapies, including monoclonal antibodies, antibody drug conjugates (ADCs) and bispecific antibodies. Our Core Business Model and Pipeline Our core business model is to in-house discover and develop innovative therapies based on differentiated or clinically-validated mechanisms of action. To complement our in-house research and development efforts, we also collaborate with third parties on the development and commercialization of our drug candidates through joint venture or out-licensing arrangements. For details, please refer to paragraphs headed “Business – Collaboration Agreements” in this prospectus. We have established a pipeline of nine IND-enabling and clinical stage drug candidates, including five in clinical stage. Source: Keymed Bio-B (02162) Prospectus (IPO Date : 2021/06/25)
Listing Market	MAIN
Industry	Biotechnology
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Bo CHEN & Associates (27.79%) Boyu Group, LLC (5.39%)
Directors	Bo CHEN (Chairman and Chief Executive Officer and Executive Director) Changyu WANG (Senior Vice President and Executive Director) Gang XU (Senior Vice President and Executive Director) Min Chuan WANG (Non-Executive Director) Qi CHEN (Non-Executive Director) Yilun Liu (Non-Executive Director) Cheuk Kin Stephen Law (Independent Non-Executive Director) Xiao-Fan Wang (Independent Non-Executive Director) Yang Ke (Independent Non-Executive Director)
Company Secretary	Yanrong ZHANG Vivien Pak Yu TAM
Principal Bankers	China Merchants Bank China Minsheng Banking Corp. Ltd.
Solicitors
Auditors	Ernst & Young
Registered Office	Room 1701, Lippo Centre Tower 2, Queensway, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.keymedbio.com
Email Address	pr@keymedbio.com
Tel No	(86 28) 8861-0620
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates